Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol
Copyright © 2020 Elsevier Inc. All rights reserved..
INTRODUCTION: Daratumumab is approved for the treatment of multiple myeloma in both frontline and relapsed/refractory settings. Its major limitation is the long infusion time, especially with the first dose. Recent data demonstrated the feasibility of infusing daratumumab at an accelerated rate of 90 minutes starting from cycle 1 on day 15. Herein, we report the safety profile and cost associated with rapid daratumumab infusion protocol.
PATIENTS AND METHODS: A chart review was performed to identify patients who completed at least 1 cycle of daratumumab (single agent or in combination) from April 2016 to October 2018. Patients were divided into 2 cohorts: cohort 1 received rapid daratumumab infusion after its implementation in March 2018, whereas cohort 2 included patients treated with daratumumab administered at the standard rate. The primary endpoint was to compare differences in rates of infusion-related reactions (IRRs). An Excel (Microsoft)-based model was developed to estimate cost and productivity.
RESULTS: A total of 100 patients with relapsed/refractory disease were included in this study (53 in cohort 1 and 47 in cohort 2). Of the 53 patients in cohort 1, 18 (34%) received rapid daratumumab infusion starting with cycle 1. Overall, there was no statistically significant difference in rates of IRRs between cohort 1 and 2 (1.9% vs. 4.3%, P = .59); 1 patient in cohort 1 developed an IRR. The total costs estimated for a 52-week regimen of daratumumab infused at standard and rapid rates were $137,200 and $122,200 (P < .001), respectively.
CONCLUSION: Our findings indicate that rapid daratumumab infusion is safe and tolerable and provides cost savings for patients with relapsed/refractory disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 20(2020), 8 vom: 22. Aug., Seite 526-532.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hamadeh, Issam S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4Z63YK6E0E |
|---|
| Anmerkungen: |
Date Completed 20.08.2021 Date Revised 20.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clml.2020.02.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308650425 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308650425 | ||
| 003 | DE-627 | ||
| 005 | 20231225132202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2020.02.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308650425 | ||
| 035 | |a (NLM)32279951 | ||
| 035 | |a (PII)S2152-2650(20)30105-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hamadeh, Issam S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.08.2021 | ||
| 500 | |a Date Revised 20.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: Daratumumab is approved for the treatment of multiple myeloma in both frontline and relapsed/refractory settings. Its major limitation is the long infusion time, especially with the first dose. Recent data demonstrated the feasibility of infusing daratumumab at an accelerated rate of 90 minutes starting from cycle 1 on day 15. Herein, we report the safety profile and cost associated with rapid daratumumab infusion protocol | ||
| 520 | |a PATIENTS AND METHODS: A chart review was performed to identify patients who completed at least 1 cycle of daratumumab (single agent or in combination) from April 2016 to October 2018. Patients were divided into 2 cohorts: cohort 1 received rapid daratumumab infusion after its implementation in March 2018, whereas cohort 2 included patients treated with daratumumab administered at the standard rate. The primary endpoint was to compare differences in rates of infusion-related reactions (IRRs). An Excel (Microsoft)-based model was developed to estimate cost and productivity | ||
| 520 | |a RESULTS: A total of 100 patients with relapsed/refractory disease were included in this study (53 in cohort 1 and 47 in cohort 2). Of the 53 patients in cohort 1, 18 (34%) received rapid daratumumab infusion starting with cycle 1. Overall, there was no statistically significant difference in rates of IRRs between cohort 1 and 2 (1.9% vs. 4.3%, P = .59); 1 patient in cohort 1 developed an IRR. The total costs estimated for a 52-week regimen of daratumumab infused at standard and rapid rates were $137,200 and $122,200 (P < .001), respectively | ||
| 520 | |a CONCLUSION: Our findings indicate that rapid daratumumab infusion is safe and tolerable and provides cost savings for patients with relapsed/refractory disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cost saving | |
| 650 | 4 | |a Daratumumab | |
| 650 | 4 | |a Infusion-related reactions | |
| 650 | 4 | |a Myeloma | |
| 650 | 4 | |a Rapid-infusion | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a daratumumab |2 NLM | |
| 650 | 7 | |a 4Z63YK6E0E |2 NLM | |
| 700 | 1 | |a Reese, Emily S |e verfasserin |4 aut | |
| 700 | 1 | |a Arnall, Justin R |e verfasserin |4 aut | |
| 700 | 1 | |a Kachur, Ekaterina |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Allison L |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Meghan |e verfasserin |4 aut | |
| 700 | 1 | |a Friend, Reed |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Barry |e verfasserin |4 aut | |
| 700 | 1 | |a Atrash, Shebli |e verfasserin |4 aut | |
| 700 | 1 | |a Bhutani, Manisha |e verfasserin |4 aut | |
| 700 | 1 | |a Voorhees, Peter M |e verfasserin |4 aut | |
| 700 | 1 | |a Usmani, Saad Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 20(2020), 8 vom: 22. Aug., Seite 526-532.e1 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:8 |g day:22 |g month:08 |g pages:526-532.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2020.02.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 8 |b 22 |c 08 |h 526-532.e1 | ||